Synopsis
Synopsis
0
CEP/COS
0
VMF
0
FDF
0
South Africa
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-t-butyl-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
2. Bosentan Anhydrous
3. Bosentan Monohydrate
4. Ro 47 0203
5. Ro 47-0203
6. Ro 470203
7. Ro-47-0203
8. Tracleer
1. 147536-97-8
2. Tracleer
3. Actelion
4. Bosentan Anhydrous
5. Ro 47-0203
6. Ro-47-0203
7. Anhydrous Bosentan
8. Bosentan [usan:inn:ban]
9. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
10. P-tert-butyl-n-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
11. Bosentan (inn)
12. 4-(tert-butyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)benzenesulfonamide
13. Chembl957
14. Xul93r30k2
15. N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide
16. Chebi:51450
17. 147536-97-8 (free)
18. 174227-18-0
19. Benzenesulfonamide, 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)-
20. Ncgc00167440-01
21. Bosentan [inn]
22. Dsstox_cid_26627
23. Dsstox_rid_81776
24. Dsstox_gsid_46627
25. 1174918-31-0
26. 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) Benzenesulfornamide
27. 4-tert-butyl-n-[6-(2-hydroxyethyloxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]benzenesulfonamide
28. Benzenesulfonamide, 4-(1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-
29. Bosentanum
30. Ro-47-0203/029
31. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide
32. Cas-147536-97-8
33. Ro 47-0203/039
34. Sr-05000001532
35. Ro-470203029
36. Ro-47-0203-029
37. Unii-xul93r30k2
38. 4-tert-butyl-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
39. 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide
40. Ks-5062
41. Starbld0043886
42. Bosentan [mi]
43. Ro-47-0203/039
44. Bosentan [who-dd]
45. Schembl4218
46. Gtpl3494
47. Dtxsid7046627
48. Hms2090n14
49. Hms3652f15
50. Hms3715n05
51. Hms3750a13
52. Bcp05202
53. Hy-a0013
54. Zinc1538857
55. Tox21_112444
56. Ac-148
57. Bdbm50061101
58. Pdsp1_001731
59. Pdsp2_001714
60. S4220
61. Akos015852063
62. Tox21_112444_1
63. Am84442
64. Bcp9000445
65. Ccg-221182
66. Cs-0381
67. Db00559
68. Sb17356
69. Ncgc00167440-02
70. Bb164259
71. B5118
72. Ft-0658809
73. Sw199648-3
74. D07538
75. W18800
76. Ab01275536-01
77. 212b550
78. A808658
79. L001086
80. Q419769
81. J-008366
82. Sr-05000001532-1
83. Sr-05000001532-2
84. Sr-05000001532-4
85. Z1541632805
86. 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2''-bipyrimidin)-4-yl) Benzenesulfornamide
87. 4-(1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide
88. 4-(tert-butyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide
89. 4-tert Butyl-n-[4-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)pyrimidin-6-yl]benzenesulphonamide
90. 4-tert-butyl-n-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-benzenesulfonamide
91. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidine]-4-yl]benzene-1-sulfonamide
92. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2''-bipyrimidin-4-yl]benzenesulfonamide
93. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide
94. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide
95. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzenesulfonamide
96. K86
Molecular Weight | 551.6 g/mol |
---|---|
Molecular Formula | C27H29N5O6S |
XLogP3 | 3.8 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 11 |
Exact Mass | 551.18385484 g/mol |
Monoisotopic Mass | 551.18385484 g/mol |
Topological Polar Surface Area | 154 Ų |
Heavy Atom Count | 39 |
Formal Charge | 0 |
Complexity | 839 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Tracleer |
PubMed Health | Bosentan (By mouth) |
Drug Classes | Antihypertensive |
Drug Label | Tracleer is the proprietary name for bosentan, an endothelin receptor antagonist that belongs to a class of highly substituted pyrimidine derivatives, with no chiral centers. It is designated chemically as 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-me... |
Active Ingredient | Bosentan |
Dosage Form | Tablet |
Route | Oral |
Strength | 125mg; 62.5mg |
Market Status | Prescription |
Company | Actelion Pharms |
2 of 2 | |
---|---|
Drug Name | Tracleer |
PubMed Health | Bosentan (By mouth) |
Drug Classes | Antihypertensive |
Drug Label | Tracleer is the proprietary name for bosentan, an endothelin receptor antagonist that belongs to a class of highly substituted pyrimidine derivatives, with no chiral centers. It is designated chemically as 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-me... |
Active Ingredient | Bosentan |
Dosage Form | Tablet |
Route | Oral |
Strength | 125mg; 62.5mg |
Market Status | Prescription |
Company | Actelion Pharms |
Used in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).
FDA Label
Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:
- Primary (idiopathic and familial) PAH;
- PAH secondary to scleroderma without significant interstitial pulmonary disease;
- PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology.
Some improvements have also been shown in patients with PAH WHO functional class II.
Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.
Bosentan belongs to a class of drugs known as endothelin receptor antagonists (ERAs). Patients with PAH have elevated levels of endothelin, a potent blood vessel constrictor, in their plasma and lung tissue. Bosentan blocks the binding of endothelin to its receptors, thereby negating endothelin's deleterious effects.
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Endothelin Receptor Antagonists
Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN RECECPTORS. (See all compounds classified as Endothelin Receptor Antagonists.)
C02KX01
C02KX01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
C - Cardiovascular system
C02 - Antihypertensives
C02K - Other antihypertensives
C02KX - Antihypertensives for pulmonary arterial hypertension
C02KX01 - Bosentan
Absorption
Absolute bioavailability is approximately 50% and food does not affect absorption.
Route of Elimination
Bosentan is eliminated by biliary excretion following metabolism in the liver.
Volume of Distribution
18 L
Clearance
4 L/h [patients with pulmonary arterial hypertension]
Bosentan is metabolized in the liver by the cytochrome P450 enzymes CYP2C9 and CYP3A4 (and possibly CYP2C19), producing three metabolites, one of which, Ro 48-5033, is pharmacologically active and may contribute 10 to 20% to the total activity of the parent compound.
Bosentan has known human metabolites that include 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-[2,2-]bipyrimidinyl-4-yl]-benzenesulfonamide and Hydroxy Bosentan.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Terminal elimination half-life is about 5 hours in healthy adult subjects.
Endothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ETA and ETB receptors in the endothelium and vascular smooth muscle. It displays a slightly higher affinity towards ETA receptors than ETB receptors. ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial hypertension, suggesting a pathogenic role for ET-1 in this disease. Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB.
Zach System is committed to providing Highly Customized Solutions for all your Development Programs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-08-25
Pay. Date : 2014-01-31
DMF Number : 24929
Submission : 2011-05-09
Status : Active
Type : II
Available Reg Filing : ASMF |
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-09-09
Pay. Date : 2015-03-04
DMF Number : 29001
Submission : 2015-03-03
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Malladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.
Date of Issue : 2022-06-08
Valid Till : 2025-07-14
Written Confirmation Number : WC-0093
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-10-13
Pay. Date : 2015-07-09
DMF Number : 26038
Submission : 2012-05-09
Status : Active
Type : II
Date of Issue : 2022-06-08
Valid Till : 2025-06-16
Written Confirmation Number : WC-0037
Address of the Firm :
NDC Package Code : 58032-2016
Start Marketing Date : 2017-12-14
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26632
Submission : 2013-03-05
Status : Active
Type : II
Registration Number : 227MF10204
Registrant's Address : Sarkhej-Dholka Road, Bhat, Ahmedabad-382 210, Gujarat, INDIA
Initial Date of Registration : 2015-08-10
Latest Date of Registration : --
Date of Issue : 2022-09-01
Valid Till : 2025-07-02
Written Confirmation Number : WC-0074
Address of the Firm :
NDC Package Code : 65691-0084
Start Marketing Date : 2013-03-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36018
Submission : 2021-09-09
Status : Active
Type : II
Date of Issue : 2019-07-26
Valid Till : 2022-05-05
Written Confirmation Number : WC-0362
Address of the Firm :
NDC Package Code : 69037-0005
Start Marketing Date : 2001-11-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-05-22
Pay. Date : 2018-04-27
DMF Number : 32757
Submission : 2018-04-30
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
4- (1,1-dimethylethyl)-N-[6-chloro-5- (2-methoxyph...
CAS Number : 150727-06-3
End Use API : Bosentan Hydrate
About The Company : Established in 1975, Acharya Group is a trusted and well-established chemical manufacturing company renowned for its commitment to technological excellence. Ach...
tert-Butyl benzene sulfonamide
CAS Number : 6292-59-7
End Use API : Bosentan Hydrate
About The Company : The Bakul Group of companies headquartered in Mumbai, India are engaged in the development and manufacture of high-quality Active Pharmaceutical Ingredients (AP...
Diethyl (O-Methoxy Phenoxy) Malonate
CAS Number : 150726-89-9
End Use API : Bosentan Hydrate
About The Company : Ramdev Chemicals Pvt. Ltd. is one of the fastest growing Active Pharmaceuticl Drugs, Drug Intermediates, Storage Fine Chemical Company in India which have speci...
CAS Number : 138588-40-6
End Use API : Bosentan Hydrate
About The Company : Ramdev Chemicals Pvt. Ltd. is one of the fastest growing Active Pharmaceuticl Drugs, Drug Intermediates, Storage Fine Chemical Company in India which have speci...
4 Tertbutyl Benzenesulfonamide
CAS Number : 6292-59-7
End Use API : Bosentan Hydrate
About The Company : We are a top producer of Pharmaceutical Intermediates, Specialty Chemicals, and More, with origins dating back to 1998. Globally renowned for its Organic Compou...
2-Amidinopyrimidine hydrochloride
CAS Number : 138588-40-6
End Use API : Bosentan Hydrate
About The Company : Sandoo Pharmaceuticals and Chemcials Co.,Ltd was established in 2009, with a young and active team, located in Ningbo, China. Specializes in exporting and imp...
Regulatory Info :
Registration Country : Italy
Brand Name : BOSENTAN ABDI
Dosage Form : Film-Coated Tablets
Dosage Strength : 125 mg
Packaging : 56 UNITS 125 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Sweden
Brand Name : bosentan Actavis
Dosage Form : FILM COATED PILL
Dosage Strength : 62.5 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Tracleer
Dosage Form : Bosentan 32Mg 56 Combined Oral Use
Dosage Strength : 56 cpr dispers 32 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Brand Name : Trac Leer
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 62.5 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Sweden
Brand Name : bosentan Aurobindo
Dosage Form : FILM COATED PILL
Dosage Strength : 125 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : TRACLEER
Dosage Form : Coated Tablets
Dosage Strength : 125 mg
Packaging : 56 UNITS 125 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : TRACLEER
Dosage Form : Coated Tablets
Dosage Strength : 62.5 mg
Packaging : 56 UNITS 62.5 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Switzerland
Brand Name : Tracleer
Dosage Form : Filmtable
Dosage Strength : 125mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Italy
Brand Name : BOSENTAN TEVA
Dosage Form : Film-Coated Tablets
Dosage Strength : 125 mg
Packaging : 56 UNITS 125 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info : Generic
Registration Country : Turkey
Brand Name :
Dosage Form : FILM COATED TABLET
Dosage Strength : 62.5MG
Packaging : 56 Tablets
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Turkey
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Bosentan Hydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bosentan Hydrate, including repackagers and relabelers. The FDA regulates Bosentan Hydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bosentan Hydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Bosentan Hydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Bosentan Hydrate supplier is an individual or a company that provides Bosentan Hydrate active pharmaceutical ingredient (API) or Bosentan Hydrate finished formulations upon request. The Bosentan Hydrate suppliers may include Bosentan Hydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Bosentan Hydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Bosentan Hydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Bosentan Hydrate active pharmaceutical ingredient (API) in detail. Different forms of Bosentan Hydrate DMFs exist exist since differing nations have different regulations, such as Bosentan Hydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Bosentan Hydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Bosentan Hydrate USDMF includes data on Bosentan Hydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Bosentan Hydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Bosentan Hydrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Bosentan Hydrate Drug Master File in Japan (Bosentan Hydrate JDMF) empowers Bosentan Hydrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Bosentan Hydrate JDMF during the approval evaluation for pharmaceutical products. At the time of Bosentan Hydrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Bosentan Hydrate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Bosentan Hydrate Drug Master File in Korea (Bosentan Hydrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Bosentan Hydrate. The MFDS reviews the Bosentan Hydrate KDMF as part of the drug registration process and uses the information provided in the Bosentan Hydrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Bosentan Hydrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Bosentan Hydrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Bosentan Hydrate suppliers with KDMF on PharmaCompass.
A Bosentan Hydrate written confirmation (Bosentan Hydrate WC) is an official document issued by a regulatory agency to a Bosentan Hydrate manufacturer, verifying that the manufacturing facility of a Bosentan Hydrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Bosentan Hydrate APIs or Bosentan Hydrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Bosentan Hydrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Bosentan Hydrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bosentan Hydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Bosentan Hydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Bosentan Hydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Bosentan Hydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bosentan Hydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Bosentan Hydrate suppliers with NDC on PharmaCompass.
Bosentan Hydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bosentan Hydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bosentan Hydrate GMP manufacturer or Bosentan Hydrate GMP API supplier for your needs.
A Bosentan Hydrate CoA (Certificate of Analysis) is a formal document that attests to Bosentan Hydrate's compliance with Bosentan Hydrate specifications and serves as a tool for batch-level quality control.
Bosentan Hydrate CoA mostly includes findings from lab analyses of a specific batch. For each Bosentan Hydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bosentan Hydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Bosentan Hydrate EP), Bosentan Hydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bosentan Hydrate USP).
LOOKING FOR A SUPPLIER?